MRNA therapy takes on autoimmune diseases in early trial

NCT ID NCT06747156

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 20 times

Summary

This early-phase study tests a new mRNA-based drug (ABO2203) designed to help control autoimmune diseases that haven't responded to standard treatments. About 66 adults with conditions like lupus or rheumatoid arthritis will receive the therapy to see if it is safe and shows signs of working. The goal is to reduce disease activity, but ongoing management may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Nanjing Drum Tower Hospital
RECRUITING

Nanjing, Jiangsu, 210000, China

Contact

Contact
Ruijin Hospital
RECRUITING

Shanghai, China

Contact
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NOT_YET_RECRUITING

Wuhan, Hubei, 430022, China

Contact

Contact

Conditions

Explore the condition pages connected to this study.

AUTOIMMUNE DISEASES